<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="infect birds (gamma and deltacoronaviruses) and several mammalian species (mainly" exact="alpha" post="and betacoronaviruses), including humans.10,11 Coronaviruses have been isolated from"/>
 <result pre="seven coronaviruses that can infect humans (HCoVs) are classified in" exact="alpha" post="coronavirus (229E, NL63) or beta coronavirus [OC43, HKU1, Middle"/>
 <result pre="include FDA-approved antivirals, such as inhibitors of HIV-1 [e. g.," exact="lopinavir" post="(1) /ritonavir (2)] and HCV [e.g., boceprevir (3)] proteases,"/>
 <result pre="HIV-1 [e. g., lopinavir (1) /ritonavir (2)] and HCV [e.g.," exact="boceprevir" post="(3)] proteases, as well as antineoplastic [e.g. carmofur (4)]"/>
 <result pre="as well as antineoplastic [e.g. carmofur (4)] and antibacterial [e.g.," exact="doxycycline" post="(5)] drugs.73,78,79,80,81,82 Chemical structures for compounds 1-14 are shown"/>
 <result pre="Putative inhibitors of SARS-CoV-2 PLpro include FDA-approved drugs such as" exact="fostamatinib" post="disodium (6) (a tyrosine kinase inhibitor used in the"/>
 <result pre="from SARS-CoV-2, as demonstrated for remdesivir (8) (Fig. 6B), an" exact="adenosine" post="triphosphate analog.92,93,96 Other potential inhibitors include clinically available drugs,"/>
 <result pre="nucleic acid analog used in the treatment of influenza, and" exact="ribavirin" post="(10), a synthetic guanosine nucleoside indicated for the treatment"/>
 <result pre="immunodeficiency syndrome (AIDS), such as vapreotide (11) (somatostatin analog) and" exact="atazanavir" post="(12) (HIV protease inhibitor), as well anti-HCV protease inhibitors"/>
 <result pre="(12) (HIV protease inhibitor), as well anti-HCV protease inhibitors [e.g.," exact="daclatasvir" post="(13)] and bismuth salts [e.g., bismuth potassium citrate (14),"/>
 <result pre="regarded as potential inhibitors of SARS-CoV-2 methyl transferases, such as" exact="adenine" post="dinucleoside S-adenosylmethionine analogs [e.g., dinucleoside 13 (15)], predicted for"/>
 <result pre="potential inhibitors of SARS-CoV-2 methyl transferases, such as adenine dinucleoside" exact="S-adenosylmethionine" post="analogs [e.g., dinucleoside 13 (15)], predicted for SARS-CoV N7-MTase"/>
 <result pre="including COVID-19.67,122,123,125 This can be exemplified by the FDA-approved drugs" exact="gliclazide" post="(17), a sulfonylurea administered to non-insulin-dependent diabetes mellitus patients,"/>
 <result pre="(17), a sulfonylurea administered to non-insulin-dependent diabetes mellitus patients, and" exact="memantine" post="(18), an N-methyl-D-aspartate receptor antagonist used in the management"/>
 <result pre="an anti-SARS-CoVs activity by disturbing ACE2 glycosylation, as proposed for" exact="chloroquine" post="(20).131 Renin-angiotensin-aldosterone system (RAAS) inhibitors, such as ACE inhibitors"/>
 <result pre="Renin-angiotensin-aldosterone system (RAAS) inhibitors, such as ACE inhibitors [ACE-i, e.g.," exact="captopril" post="(21)] and angiotensin receptor blockers [ARB, e.g., losartan (22)],"/>
 <result pre="stages.65,138 Potential TMPRSS2 blockers include some serine protease inhibitors [e.g.," exact="camostat" post="mesylate (23)], commercially available compounds [e. g., ZINC64606047 (24),"/>
 <result pre="agents that increase endosomal pH (avoiding cathepsin L activation) [e.g.," exact="chloroquine" post="(20) and hydroxychloroquine (26)] and cathepsin L inhibitors [e.g.,"/>
 <result pre="endosomal pH (avoiding cathepsin L activation) [e.g., chloroquine (20) and" exact="hydroxychloroquine" post="(26)] and cathepsin L inhibitors [e.g., teicoplanin (27), a"/>
 <result pre="role in COVID-19 management.66 Dipeptidyl peptidase-4 (DDP4), also known as" exact="adenosine" post="deaminase complexing protein 2 or T-cell activation antigen CD26,"/>
 <result pre="a discussion about the use of DDP4 inhibitors, such as" exact="sitagliptin" post="(29) (anti-diabetic drug), in the treatment of COVID-19.152,153,155,156 In"/>
 <result pre="drug Previous use Predicted targets Discovery origin Experimental evidence Reference" exact="Pemirolast" post="(30), nitrofurantoin (31), isoniazid pyruvate (32), eriodictyol (33), cepharanthine"/>
 <result pre="use Predicted targets Discovery origin Experimental evidence Reference Pemirolast (30)," exact="nitrofurantoin" post="(31), isoniazid pyruvate (32), eriodictyol (33), cepharanthine (34), ergoloid"/>
 <result pre="targets Discovery origin Experimental evidence Reference Pemirolast (30), nitrofurantoin (31)," exact="isoniazid" post="pyruvate (32), eriodictyol (33), cepharanthine (34), ergoloid (35) and"/>
 <result pre="Discovery origin Experimental evidence Reference Pemirolast (30), nitrofurantoin (31), isoniazid" exact="pyruvate" post="(32), eriodictyol (33), cepharanthine (34), ergoloid (35) and hypericin"/>
 <result pre="assays Mefuparib (37) achieved an EC50 of 5.12 Î¼M. 164" exact="Atazanavir" post="(12) and efavirenz (38) HIV SARS-CoV-2 3C-like protease (Mpro)"/>
 <result pre="achieved an EC50 of 5.12 Î¼M. 164 Atazanavir (12) and" exact="efavirenz" post="(38) HIV SARS-CoV-2 3C-like protease (Mpro) Molecule transformer drug-target"/>
 <result pre="HIV SARS-CoV-2 3C-like protease (Mpro) Molecule transformer drug-target interaction (MT-DTI)" exact="Atazanavir" post="(12) can been found in lungs after administration and"/>
 <result pre="cough and dyspnea) in a small group of patients.c 161" exact="Toremifene" post="(40), sirolimus (41), mercaptopurine (42), irbesartan (43) Multiple Multiple"/>
 <result pre="dyspnea) in a small group of patients.c 161 Toremifene (40)," exact="sirolimus" post="(41), mercaptopurine (42), irbesartan (43) Multiple Multiple targets in"/>
 <result pre="a small group of patients.c 161 Toremifene (40), sirolimus (41)," exact="mercaptopurine" post="(42), irbesartan (43) Multiple Multiple targets in humans and"/>
 <result pre="group of patients.c 161 Toremifene (40), sirolimus (41), mercaptopurine (42)," exact="irbesartan" post="(43) Multiple Multiple targets in humans and coronaviruses Systems"/>
 <result pre="network Antiviral activities against coronaviruses has been described for selective" exact="estrogen" post="modulators toremifene (40), immunosuppressants sirolimus (41) and mercaptopurine (42)"/>
 <result pre="activities against coronaviruses has been described for selective estrogen modulators" exact="toremifene" post="(40), immunosuppressants sirolimus (41) and mercaptopurine (42) and angiotensin"/>
 <result pre="has been described for selective estrogen modulators toremifene (40), immunosuppressants" exact="sirolimus" post="(41) and mercaptopurine (42) and angiotensin receptor blockers irbesartan"/>
 <result pre="for selective estrogen modulators toremifene (40), immunosuppressants sirolimus (41) and" exact="mercaptopurine" post="(42) and angiotensin receptor blockers irbesartan (43).d 52 a:"/>
 <result pre="immunosuppressants sirolimus (41) and mercaptopurine (42) and angiotensin receptor blockers" exact="irbesartan" post="(43).d 52 a: Cepharanthin (34) has been shown to"/>
 <result pre="and other flavonoids on SARS-CoV-2.166,167b: a recent study showed that" exact="Atazanavir" post="(12) inhibited Mproin vitro with greater potency than lopinavir"/>
 <result pre="that Atazanavir (12) inhibited Mproin vitro with greater potency than" exact="lopinavir" post="(1).168c: despite the small size (12 patients) and open"/>
 <result pre="baricitinib (39) showed potential safety when used in combination with" exact="lopinavir" post="(1) / ritonavir (2).169 As of August 3rd 13th,"/>
 <result pre="potential safety when used in combination with lopinavir (1) /" exact="ritonavir" post="(2).169 As of August 3rd 13th, 2020, there are"/>
 <result pre="the isolated proteins. From this analysis, four compounds [pemirolast (30)," exact="nitrofurantoin" post="(31), isoniazid pyruvate (32) and eriodictyol (33)] displayed potential"/>
 <result pre="proteins. From this analysis, four compounds [pemirolast (30), nitrofurantoin (31)," exact="isoniazid" post="pyruvate (32) and eriodictyol (33)] displayed potential to disrupt"/>
 <result pre="From this analysis, four compounds [pemirolast (30), nitrofurantoin (31), isoniazid" exact="pyruvate" post="(32) and eriodictyol (33)] displayed potential to disrupt the"/>
 <result pre="of small compounds and protein targets. The authors found that" exact="atazanavir" post="(12), remdesivir (8) and efavirenz (38) are potential inhibitors"/>
 <result pre="targets. The authors found that atazanavir (12), remdesivir (8) and" exact="efavirenz" post="(38) are potential inhibitors of Mpro, while atazanavir (12)"/>
 <result pre="(8) and efavirenz (38) are potential inhibitors of Mpro, while" exact="atazanavir" post="(12) also yielded nanomolar predicted binding affinity for RdRP,"/>
 <result pre="selected by the authors are from a diverse set, including" exact="toremifene" post="(40) (selective estrogen receptor modulator), sirolimus (41) (immunosuppressant), mercaptopurine"/>
 <result pre="authors are from a diverse set, including toremifene (40) (selective" exact="estrogen" post="receptor modulator), sirolimus (41) (immunosuppressant), mercaptopurine (42) (antineoplastic) and"/>
 <result pre="a diverse set, including toremifene (40) (selective estrogen receptor modulator)," exact="sirolimus" post="(41) (immunosuppressant), mercaptopurine (42) (antineoplastic) and irbesartan (43) (antihypertensive)."/>
 <result pre="including toremifene (40) (selective estrogen receptor modulator), sirolimus (41) (immunosuppressant)," exact="mercaptopurine" post="(42) (antineoplastic) and irbesartan (43) (antihypertensive). An interesting finding"/>
 <result pre="estrogen receptor modulator), sirolimus (41) (immunosuppressant), mercaptopurine (42) (antineoplastic) and" exact="irbesartan" post="(43) (antihypertensive). An interesting finding was that the selected"/>
 <result pre="of Coronavirus-related disease, such as emodin (44) in SARS-CoV, and" exact="mercaptopurine" post="(42) and toremifene (40) in SARS-CoV and MERS-CoV.52 In"/>
 <result pre="such as emodin (44) in SARS-CoV, and mercaptopurine (42) and" exact="toremifene" post="(40) in SARS-CoV and MERS-CoV.52 In addition to identifying"/>
 <result pre="between them were also suggested by the network, such as" exact="sirolimus" post="(41) and dactinomycin (45), and mercaptopurine (42) and melatonin"/>
 <result pre="also suggested by the network, such as sirolimus (41) and" exact="dactinomycin" post="(45), and mercaptopurine (42) and melatonin (46).52 In vitro"/>
 <result pre="the network, such as sirolimus (41) and dactinomycin (45), and" exact="mercaptopurine" post="(42) and melatonin (46).52 In vitro and in vivo"/>
 <result pre="as sirolimus (41) and dactinomycin (45), and mercaptopurine (42) and" exact="melatonin" post="(46).52 In vitro and in vivo studies - Genome"/>
 <result pre="Reference Remdesivir (8) Ebola RNA polymerase 0.77 Î¼M 129.9 194" exact="Chloroquine" post="(20) / Hydroxychloroquine (26) Malaria / Lupus and rheumatoid"/>
 <result pre="Ebola RNA polymerase 0.77 Î¼M 129.9 194 Chloroquine (20) /" exact="Hydroxychloroquine" post="(26) Malaria / Lupus and rheumatoid arthritis Acidification in"/>
 <result pre="/ 14.4 to 61.5 depending on multiplicities of infection 194,195,196" exact="Ritonavir" post="(2) + lopinavir (1) HIV 3-chymotrypsin-like protease (3CLpro) and"/>
 <result pre="61.5 depending on multiplicities of infection 194,195,196 Ritonavir (2) +" exact="lopinavir" post="(1) HIV 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro)"/>
 <result pre="inhibited virus infection efficiently in human liver cancer Huh-7 cells." exact="Chloroquine" post="(CQ; 20) and its less toxic derivative, hydroxychloroquine (HCQ;"/>
 <result pre="Huh-7 cells. Chloroquine (CQ; 20) and its less toxic derivative," exact="hydroxychloroquine" post="(HCQ; 26), are used to treat malaria and lupus/rheumatoid"/>
 <result pre="(20) itself.207 It is also good to point out that" exact="chloroquine" post="(20) has shown in vitro activity against many different"/>
 <result pre="but no significant beneficial effect on animal models.208 The association" exact="ritonavir" post="(2)/lopinavir (1) is used together with other antiretrovirals for"/>
 <result pre="of human immunodeficiency virus since the beginning of the century.209" exact="Ritonavir" post="(2) is a potent CYP3A inhibitor therefore inhibiting the"/>
 <result pre="is a potent CYP3A inhibitor therefore inhibiting the metabolism of" exact="lopinavir" post="(1), increasing its plasma levels. Both are reported as"/>
 <result pre="Wilde et al. that demonstrated antiviral in vitro effect of" exact="lopinavir" post="(1), but not ritonavir (2), against SARS-CoV, MERS-CoV, and"/>
 <result pre="demonstrated antiviral in vitro effect of lopinavir (1), but not" exact="ritonavir" post="(2), against SARS-CoV, MERS-CoV, and hCoV-229E, with mean EC50"/>
 <result pre="most promising therapies: remdesivir (8); CQ (20) or HCQ (26);" exact="ritonavir" post="(2)/lopinavir (1); ritonavir (2) /lopinavir (1) plus interferon-beta, an"/>
 <result pre="remdesivir (8); CQ (20) or HCQ (26); ritonavir (2)/lopinavir (1);" exact="ritonavir" post="(2) /lopinavir (1) plus interferon-beta, an immune response modulator.44"/>
 <result pre="compared to placebo group (11 vs 15 days) 216; NCT04280705" exact="Chloroquine" post="(20) Multicentre &amp;gt; 100 patients 500 mg per day,"/>
 <result pre="day, once daily for more 4 days Higher dosage of" exact="chloroquine" post="(20) has toxic effects and increased lethality, with any"/>
 <result pre="toxic effects and increased lethality, with any clinical benefit 218" exact="Hydroxychloroquine" post="(26) non-randomised, non-double-blind, non-placebo-controlled 36 patients 600 mg of"/>
 <result pre="Hydroxychloroquine (26) non-randomised, non-double-blind, non-placebo-controlled 36 patients 600 mg of" exact="hydroxychloroquine" post="(26) daily for 10 days Hydroxychloroquine (26) significantly reduces"/>
 <result pre="patients 600 mg of hydroxychloroquine (26) daily for 10 days" exact="Hydroxychloroquine" post="(26) significantly reduces viral load despite small sample size"/>
 <result pre="(26) significantly reduces viral load despite small sample size 219" exact="Ritonavir" post="(2)/lopinavir (1) Randomised, controlled, open-label 199 patients 400 mg/100"/>
 <result pre="a day for 14 days No benefit was observed with" exact="lopinavir" post="(1)-ritonavir (2) treatment compared to standard care in severe"/>
 <result pre="treatment compared to standard care in severe Covid-19 patients 220" exact="Ritonavir" post="(2)/lopinavir (1) plus interferon Phase II, randomised, controlled, open-label"/>
 <result pre="measure the effectiveness of CQ (20) at 500 mg of" exact="chloroquine" post="diphosphate (corresponding to 300 mg of chloroquine (20) base)"/>
 <result pre="500 mg of chloroquine diphosphate (corresponding to 300 mg of" exact="chloroquine" post="(20) base) per day, for ten consecutive days on"/>
 <result pre="load in COVID-19 patients and its effect is reinforced by" exact="azithromycin" post="(AZ; 49) combination.219 Until this moment there is clinical"/>
 <result pre="patients is still expected for concluding on the efficacy of" exact="hydroxychloroquine" post="(26). Ritonavir (2) and lopinavir (1) were developed to"/>
 <result pre="still expected for concluding on the efficacy of hydroxychloroquine (26)." exact="Ritonavir" post="(2) and lopinavir (1) were developed to target HIV-1"/>
 <result pre="concluding on the efficacy of hydroxychloroquine (26). Ritonavir (2) and" exact="lopinavir" post="(1) were developed to target HIV-1 protease and postulated"/>
 <result pre="whether these drugs are useful for COVID-19 treatment or not." exact="Ritonavir" post="(2)/lopinavir (1) plus interferon-beta, a cytokine involved in inflammatory"/>
 <result pre="Infection in a Nonhuman Primate Model.233 The study (NCT04276688) administered" exact="ritonavir" post="(2)/lopinavir (1) 400 mg + 100 mg/ml twice daily"/>
 <result pre="tested in COVID-19 clinical trials include CQ (20), HCQ (26)," exact="Ritonavir" post="(2) and Lopinavir (1).239,240 A recent research article published"/>
 <result pre="optimised synthetic pathways found in patents and articles for some" exact="Ritonavir" post="(2) and Lopinavir (1) are discussed below, as CQ"/>
 <result pre="each of the drugs we had the synthesis reviewed here." exact="Ritonavir" post="(2) - The first disclosure of ritonavir (2) is"/>
 <result pre="synthesis reviewed here. Ritonavir (2) - The first disclosure of" exact="ritonavir" post="(2) is presented in a patent from 1994, assigned"/>
 <result pre="above deficiencies, a recent Chinese patent concerning the synthesis of" exact="ritonavir" post="(2) has been released. The synthetic pathway described in"/>
 <result pre="addition-elimination reaction with reagent (76), thus obtaining the final product" exact="ritonavir" post="(2) (Fig. 16).252 When comparing both patents, it is"/>
 <result pre="is ease to scale-up the production. Fig. 16: synthesis of" exact="Ritonavir" post="(2) via a cost-effective and easy synthetic pathway. Lopinavir"/>
 <result pre="- The first synthetic methods related to the synthesis of" exact="lopinavir" post="(1) are present in a patent from 1996 owned"/>
 <result pre="are similar, involving the synthesis of a key intermediate amino" exact="alcohol" post="unit, that is then connected to the appropriated side"/>
 <result pre="production. The most recent patent related to the synthesis of" exact="lopinavir" post="(1) is dated 2018 and it is from the"/>
 <result pre="1996, by Abbott Laboratories. The patent describes the synthesis of" exact="lopinavir" post="(1) by a one-pot procedure starting with the formation"/>
 <result pre="nucleophilic addition-elimination reaction to occur, affording (1) after treatment with" exact="NaHCO3" post="(Fig. 17). Therefore, it is possible to synthesise lopinavir"/>
 <result pre="with NaHCO3 (Fig. 17). Therefore, it is possible to synthesise" exact="lopinavir" post="(1) in high yield (90%) in an optimised method,"/>
 <result pre="materials, number of steps and overall yield. Regarding chiral centres," exact="ritonavir" post="(2) and lopinavir (1) have four chiral centres each,"/>
 <result pre="steps and overall yield. Regarding chiral centres, ritonavir (2) and" exact="lopinavir" post="(1) have four chiral centres each, and they are"/>
 <result pre="number of steps and lower overall yield when compared to" exact="ritonavir" post="(2) and lopinavir (1). However, one of the steps"/>
 <result pre="and lower overall yield when compared to ritonavir (2) and" exact="lopinavir" post="(1). However, one of the steps in the synthesis"/>
 <result pre="(alone or in association with other drugs) and the association" exact="lopinavir" post="(1)/ritonavir (2) have been the focus of most clinical"/>
 <result pre="inhibitors of coronavirus RNA cap guanine-N7-methyltransferaseAntiviral Res201410415616424530452 112Ahmed-BelkacemRSutto-OrtizPGuiraudMCanardBVasseur J-JDecrolyESynthesis of" exact="adenine" post="dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14"/>
 <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596010596032251731 119StopsackKHMucciLAAntonarakisESNelsonPSKantoffPWTMPRSS2"/>
 <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596010596032251731 119StopsackKHMucciLAAntonarakisESNelsonPSKantoffPWTMPRSS2 and COVID-19"/>
 <result pre="is a potential ion channel that can be inhibited by" exact="Gliclazide" post="and MemantineBiochem Biophys Res Commun20205301101432828269 127McKinneyCAFattahCLoughreyCMMilliganGNicklinSAAngiotensin-(1-7) and angiotensin-(1-9) function"/>
 <result pre="preclinical studies 131DevauxCARolain J-MColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus what to expect for COVID-19?Int J Antimicrob"/>
 <result pre="models for SARS and MERS coronavirusesCurr Opin Virol20151312312926184451 194WangMCaoRZhangLYangXLiuJXuMRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="homoharringtonine inhibit SARS-CoV-2 replication in vitroAntiviral Res202017810478610478632251767 198CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res202017810478710478732251768 199ZhangJMaXYuFLiuJZouFPanTet"/>
 <result pre="against SARS coronavirus infectionsExpert Rev Anti Infect Ther20064229130216597209 204FernerREAronsonJKChloroquine and" exact="hydroxychloroquine" post="in covid-19BMJ2020369m1432m143232269046 205Al-BariMAATargeting endosomal acidification by chloroquine analogs as"/>
 <result pre="Ther20064229130216597209 204FernerREAronsonJKChloroquine and hydroxychloroquine in covid-19BMJ2020369m1432m143232269046 205Al-BariMAATargeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
 <result pre="SARS-CoV-2 infection in vitroCell Discov202061161632194981 207McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med198375111186408923 208TouretFde LamballerieXOf chloroquine and COVID-19Antiviral Res202017710476210476232147496"/>
 <result pre="toxicity and pharmacokinetics of hydroxychloroquine sulfateAm J Med198375111186408923 208TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res202017710476210476232147496 209LvZChuYWangYHIV protease inhibitors a review of"/>
 <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 protease against COVID-19J Biomol Struct Dyn202010.1080/07391102.2020.1752802"/>
 <result pre="treatment of Covid-19 - Preliminary reportN Engl J Med202010.1056/NEJMoa2007764 217GaoJTianZYangXBreakthrough" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="clinical studiesBiosci Trends2020141727332074550 218BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMEffect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2) infectionJAMA Netw Open202034e20885732330277 219GautretPLagier J-CParolaPHoangVTMeddebLMailheMHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19 results of an open-label"/>
 <result pre="Antimicrob Agents202055410593310593332147516 225collab: FDARemdesivir EUA letter of authorization2020https://www.fda.gov/media/137564/download 226SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections an old drug against today's diseasesLancet"/>
 <result pre="against today's diseasesLancet Infect Dis200331172272714592603 227ChatreCRoubilleFVernhetHJorgensenCPers Y-MCardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine a systematic review of the literatureDrug Saf2018411091993129858838"/>
 <result pre="diseasesLancet Infect Dis200331172272714592603 227ChatreCRoubilleFVernhetHJorgensenCPers Y-MCardiac complications attributed to chloroquine and" exact="hydroxychloroquine" post="a systematic review of the literatureDrug Saf2018411091993129858838 228DamleBVourvahisMWangELeaneyJCorriganBClinical pharmacology"/>
 <result pre="literatureDrug Saf2018411091993129858838 228DamleBVourvahisMWangELeaneyJCorriganBClinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin Pharmacol Ther2020108220121132302411 229MehraMRDesaiSSKuySHenryTDPatelANRetraction cardiovascular disease,"/>
 <result pre="drug therapy, and mortality in Covid-19N Engl J Med20203822625822582 230MehraMRDesaiSSRuschitzkaFPatelAN.RETRACTED:" exact="hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
 <result pre="and mortality in Covid-19N Engl J Med20203822625822582 230MehraMRDesaiSSRuschitzkaFPatelAN.RETRACTED: hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
 <result pre="COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 231BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19N Engl J Med202010.1056/NEJMoa2016638 232ZumlaAChanJFWAzharEIHuiDSCYuen"/>
 <result pre="marmosetJ Infect Dis2015212121904191326198719 234NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaSMolecular dynamic simulations analysis of ritronavir and" exact="lopinavir" post="as SARS-CoV 3CLpro inhibitorsJ Theor Biol2008254486186718706430 235ChuCMRole of lopinavir/ritonavir"/>
 <result pre="Chem19984146026179484509 252NingZRanGRenXUZhangYIZhouZ2019Preparation method of ritonavirChinese patent 253ShoujunWDequanWUYuyouXChaoZ2018Method used for preparing" exact="lopinavir" post="using one-pot methodChinese patent"/>
</results>
